GARRY ARTHUR NEIL
CIK 1586785 · Chief Executive Officer · last filed 2026-06-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$68.62M
Companies
9
Total Filings
57
Lifetime Open-Market Net
$619.4K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CLDX | Director | — | $35.58 | — | $0 | 5 | 2026-06-29 |
| AVTX | Chief Executive Officer | 190,314 | $19.52 | $3.71M | $29.6K | 12 | 2026-05-26 |
| Zura Bio Ltd (ZURAW) Delisted | Director | — | $1.08 | — | $0 | 1 | 2023-05-22 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | Director | 0 | $99.99 | $0 | $0 | 7 | 2022-03-11 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Chief Scientific Officer | 81,372 | $2.93 | $238.4K | $20.7K | 5 | 2021-06-14 |
| GNMX | Chief Scientific Officer | 2,164,150 | $29.99 | $64.90M | $369.1K | 7 | 2019-12-09 |
| Oncternal Therapeutics, Inc. (GTXI) Delisted | Director | 5,251 | — | — | $0 | 14 | 2019-01-03 |
| Aevi Genomic Medicine, LLC (MDGN) Delisted | Chief Scientific Officer | — | — | — | $0 | 1 | 2016-04-19 |
| Aevi Genomic Medicine, LLC (MDGN.WS) Delisted | Chief Scientific Officer | 39,774 | — | — | $200.0K | 4 | 2015-10-08 |
Recent Filings · Page 2 of 6
57 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-22 | Zura Bio Ltd (ZURAW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-17 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2023-02-15 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2022-12-12 | AVTX | Buy (P) | +2,083 | $9.2K | EDGAR |
| 2022-10-07 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2022-06-17 | CLDX | Grant (A) | — | $0 | EDGAR |
| 2022-03-11 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Mixed | −11,217 | $0 | EDGAR |
| 2022-03-10 | AVTX | Grant (A) | — | $0 | EDGAR |
| 2021-12-14 | AVTX | Buy (P) | +4,267 | $6.7K | EDGAR |
| 2021-06-15 | ARENA PHARMACEUTICALS INC (ARNA) Delisted | Grant (A) | +3,067 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.